Asciminib 20 mg, 40 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20 mg, 40 mg

Reference Brands: Scemblix (USA)

Category: Oncology Cancer Care

Asciminib is a Oncology Cancer Care product available as Tablets in strengths 20 mg, 40 mg. It corresponds to the reference brand Scemblix (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Asciminib is a targeted anticancer medication used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is a novel protein kinase inhibitor with a unique mechanism of action, classified as a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket). Unlike conventional tyrosine kinase inhibitors that bind to the ATP-binding site, asciminib selectively binds to the myristoyl pocket of the BCR-ABL1 protein, resulting in effective and sustained inhibition of leukemic cell growth.

Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who have previously received two or more tyrosine kinase inhibitors. It is also approved for the treatment of adults with chronic-phase Ph+ CML harboring the T315I mutation, a mutation associated with resistance to multiple standard therapies.

Marketed under the brand name Scemblix, asciminib offers a targeted treatment option for patients with limited therapeutic alternatives. Its distinct mechanism of action supports its use in resistant or refractory cases, contributing to improved disease control and long-term management of chronic myeloid leukemia.